Brain-derived neurotrophic factor plasma levels and premature cognitive impairment/dementia in type 2 diabetes

Table 1 Clinical characteristics of hemodialysis patients

Baseline characteristics	HD patients with cognitive impairment (n = 17)	HD patients without cognitive impairment (n = 23)	P
Age (yr)	51.88 ± 12.81	42.30 ± 12.87	0.02
Duration of hemodialysis (mon)	41.29 ± 42.01	32.08 ± 36-76	0.13
BDNF (ng/mL)	11.39 ± 8.87	11.11 ± 10.64	0.77
Creatinine (mg/dL)	8.90 ± 1.90	9.21 ± 2.61	0.68
Urea (mg/dL)	128.68 ± 54.23	127.74 ± 51.54	0.77
Hemoglobin (g/dL)	12.13 ± 1.38	11.53 ± 1.92	0.51
Ferritin (ng/mL)	1564 ± 1335.05	664.22 ± 484.99	0.001
Mini-mental state examination	19.58 ± 3.24	26.08 ± 1.50	0.0001

BDNF: Brain-derived neurotrophic factor; HD: Hemodialysis therapy.

Table 2 Clinical characteristics of diabetes mellitus type 2 patients

Baseline characteristics	DM2 patients with cognitive impairment (n = 19)	DM2 patients without cognitive impairment (n = 18)	P
Age (yr)	50.57 ± 5.90	54.05 ± 3.63	0.06
Duration of DM2 (yr)	14.31 ± 6.22	9.05 ± 4.64	0.007
BDNF (ng/mL)	31.55 ± 10.24	43.78 ± 9.05	0.005
Glucose (mg/dL)	177 ± 64.91	138 ± 43.90	0.07
Glycated hemoglobin (HBA1c) (%)	8.36 ± 1.52	7.33 ± 1.42	0.02
Minimental state examination	20.26 ± 2.15	25.44 ± 1.50	0.0001

BDNF: Brain-derived neurotrophic factor; DM2: Diabetes mellitus type 2.